These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2209357)

  • 41. Treatment of Ocular Myasthenia Gravis.
    Cornblath WT
    Asia Pac J Ophthalmol (Phila); 2018; 7(4):257-259. PubMed ID: 30044061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
    Reddel SW; Morsch M; Phillips WD
    Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Italian recommendations for the diagnosis and treatment of myasthenia gravis.
    Evoli A; Antonini G; Antozzi C; DiMuzio A; Habetswallner F; Iani C; Inghilleri M; Liguori R; Mantegazza R; Massa R; Pegoraro E; Ricciardi R; Rodolico C
    Neurol Sci; 2019 Jun; 40(6):1111-1124. PubMed ID: 30778878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overcoming challenges in the diagnosis and treatment of myasthenia gravis.
    Evoli A; Iorio R; Bartoccioni E
    Expert Rev Clin Immunol; 2016; 12(2):157-68. PubMed ID: 26675896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of myasthenia gravis.
    Schwendimann RN; Burton E; Minagar A
    Am J Ther; 2005; 12(3):262-8. PubMed ID: 15891271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Neurologist's Perspective on Understanding Myasthenia Gravis: Clinical Perspectives of Etiologic Factors, Diagnosis, and Preoperative Treatment.
    Mukharesh L; Kaminski HJ
    Thorac Surg Clin; 2019 May; 29(2):133-141. PubMed ID: 30927994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The current role of thymectomy for myasthenia gravis.
    Mintz S; Petersen SR; MacFarland D; Petajan J; Richards RC
    Am J Surg; 1980 Dec; 140(6):734-7. PubMed ID: 7457692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diagnostics and treatment of myasthenia gravis in children].
    Kroczka S; Steczkowska M; Nowak A; Kaciński M
    Przegl Lek; 2008; 65(11):783-8. PubMed ID: 19205361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myasthenia gravis crisis.
    Bershad EM; Feen ES; Suarez JI
    South Med J; 2008 Jan; 101(1):63-9. PubMed ID: 18176295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [DFPP in myasthenia gravis: case report].
    Altobelli C; Pollastro RM; Marano E; Capasso G; Anastasio P
    G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myasthenial gravis; problems in diagnosis.
    HERRMANN C; ROSE AS
    Calif Med; 1957 Dec; 87(6):373-9. PubMed ID: 13489495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update on myasthenia gravis.
    Thanvi BR; Lo TC
    Postgrad Med J; 2004 Dec; 80(950):690-700. PubMed ID: 15579606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment-refractory myasthenia gravis.
    Silvestri NJ; Wolfe GI
    J Clin Neuromuscul Dis; 2014 Jun; 15(4):167-78. PubMed ID: 24872217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasmapheresis therapy in myasthenia gravis.
    Dau PC
    Muscle Nerve; 1980; 3(6):468-82. PubMed ID: 7453714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids.
    Tannemaat MR; Verschuuren JJGM
    Neuromuscul Disord; 2020 Feb; 30(2):111-119. PubMed ID: 32007304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment and clinical research in myasthenia gravis: how far have we come?
    Barohn RJ
    Ann N Y Acad Sci; 2008; 1132():225-32. PubMed ID: 18567872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Problems in the optimal management of myasthenia gravis patients--a prospective clinical survey at Kalafong Hospital.
    Mafojane NA; Bill PL; Lotz BP
    S Afr Med J; 2002 Mar; 92(3):225-30. PubMed ID: 12040952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.